Forget the AI Hype—Buy the Picks and Shovels Instead
Remember the California Gold Rush? Most prospectors went broke chasing glitter. The real money? It went to the folks selling picks, shovels, and whiskey. Turns out, 2026's AI boom is following the exact same playbook—and most investors still haven't figured it out. Here's the thing: everyone's obsessed with the flashy AI software stories. The demos, the headlines, the "this will change everything" narratives. Meanwhile, the actual money is flowing to the unglamorous companies building the machinery that makes the whole thing ...
Read More About This
Read More About This
Smart Money Is Quietly Dumping AI Stocks for Old-School Hard Assets
While retail traders debate which AI stock is the next Nvidia, institutional money is doing something unexpected: rotating into the most boring companies on the planet. Railways. Commodity producers. Defence contractors. The kind of businesses that haven't been exciting since your grandfather's portfolio. The logic is disarmingly simple. If AI really does replace most knowledge work, then the companies most at risk are the "asset-light" darlings that dominated the last decade — consulting firms, software companies, financial services. The businesses that ...
Read More About This
Read More About This
The Soros Fund CEO Just Called a ‘Massive Culling’ in Private Equity
Dawn Fitzpatrick doesn't mince words. The CEO of Soros Fund Management just told a Bloomberg audience that a "massive culling" of alternative asset managers is on the way — and the $4.4 trillion private equity industry has no one to blame but itself. Her diagnosis is surgical. For a decade, private equity managers binged on cheap money, stretched valuations, and a flood of institutional capital chasing yield. The party's over. Hold periods that used to average 4.2 years have ballooned to ...
Read More About This
Read More About This
The Market Just Priced Out Rate Cuts Until 2027 — Here’s What That Means
Two weeks ago, traders expected a Fed rate cut by June. Today, they've pushed that expectation all the way out to mid-2027 — and maybe even 2028. That's not a subtle shift. That's the market ripping up its playbook and starting over. The catalyst? Oil prices blowing past $100 a barrel after the U.S.-Israel strikes on Iran sent energy markets into panic mode. Brent crude hasn't been this disruptive since Russia invaded Ukraine. And with the Strait of Hormuz under threat, ...
Read More About This
Read More About This
Forget the AI Hype—Buy the Picks and Shovels Instead
Remember the California Gold Rush? Most prospectors went broke chasing glitter. The real money? It went to the folks selling picks, shovels, and whiskey. Turns out, 2026's AI boom is following the exact same playbook—and most investors still haven't figured it out. Here's the thing: everyone's obsessed with the flashy AI software stories. The demos, the headlines, the "this will change everything" narratives. Meanwhile, the actual money is flowing to the unglamorous companies building the machinery that makes the whole thing ...
Read More About This
Read More About This
Meta Just Dropped $27 Billion on AI Compute, and Nebius Is Suddenly Everyone’s Favorite Infrastructure Play
Remember when everyone was worried about who'd actually build all the AI data centers? Well, Meta just answered that question by throwing $27 billion at Nebius—and the market is losing its mind. Nebius stock jumped 15% on Monday, which is the kind of move that makes investors check their portfolios twice. The Dutch AI infrastructure company is now up 35% year-to-date, and honestly, it's not hard to see why. Meta just committed to buying up to $27 billion in compute capacity ...
Read More About This
Read More About This
This Small Biotech Just Matched Ozempic Results With a Pill
The weight-loss drug wars just got a lot more interesting. Structure Therapeutics — a biotech most traders have never heard of — just dropped phase 2 data showing its oral GLP-1 drug can match the results of injectable blockbusters like Ozempic and Mounjaro. The stock jumped 8% in premarket on the news. The numbers are remarkable. Aleniglipron, Structure's oral pill, delivered placebo-adjusted weight loss of 16.3% at 180mg and 16.0% at 240mg over 44 weeks — with no evidence of a ...
Read More About This
Read More About This
Defence Stocks Are Quietly Crushing Everything Else in 2026
While the S&P 500 is basically flat this year and tech stocks are getting smacked around, one sector has been quietly running circles around the market: defence. The Morningstar Global Aerospace and Defense Index is up 11.7% year-to-date. The broader global stock market? Up 0.4%. That's not a gap — that's a canyon. And the Iran conflict is only making it wider. Here's what's driving the move. Europe is scrambling to rearm after decades of letting the U.S. foot the bill. Germany ...
Read More About This
Read More About This